GlassScriptPhysician profile
Michael C Shipman
NPI 1437159951
$12,299.83
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,891 · 2022: $2,902 · 2023: $3,386 · 2024: $3,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,507.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,819.71 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,639.99 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,414.54 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $954.06 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $853.82 | 2021-2024 | |
| Glaxosmithkline, LLC. | $599.74 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.50 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $480.78 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.08 | 2021-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $404.33 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Sanofi-Aventis U.S. LLC | $300.30 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $286.77 | 2021-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $256.29 | 2022 | |
| Amarin Pharma, INC. | $241.60 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $241.06 | 2022-2024 | Xarelto |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $212.70 | 2024 | Voquezna |
| Exact Sciences Corporation | $204.24 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $188.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $135.28 | 2022-2024 | |
| Lundbeck LLC | $124.97 | 2022-2024 | Rexulti |
| Mylan Specialty L.P. | $103.41 | 2022-2023 | Yupelri |
| Abbott Laboratories | $93.41 | 2021-2024 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $84.06 | 2023 | Uptravi, Opsumit |
| Ironwood Pharmaceuticals, INC | $72.72 | 2023 | Linzess |
| Astellas Pharma US INC | $72.37 | 2024 | Veozah |
| Corcept Therapeutics | $72.03 | 2023-2024 | Korlym |
| Dexcom, INC. | $61.05 | 2021-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $51.55 | 2021-2024 | |
| Ibsa Pharma INC. | $44.94 | 2023 | Tirosint, Licart |
| Lexicon Pharmaceuticals, INC. | $38.42 | 2024 | |
| Nestle Healthcare Nutrition INC. | $34.01 | 2021-2023 | |
| Organon LLC | $29.66 | 2022-2023 | Nexplanon |
| Kowa Pharmaceuticals America, INC. | $28.75 | 2023 | Seglentis, Livalo |
| Esperion Therapeutics, INC. | $26.74 | 2021 | |
| Sage Therapeutics, LLC | $26.65 | 2024 | |
| Amgen INC. | $22.76 | 2022 | |
| Sanofi Pasteur INC. | $21.87 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.12 | 2024 | Quviviq |
| Gilead Sciences, INC. | $17.79 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.64 | 2023 | Qelbree |
| Hologic Sales and Service, LLC | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.